{"id":"NCT01392547","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors","officialTitle":"Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2011-07-12","resultsPosted":"2013-12-06","lastUpdate":"2017-05-15"},"enrollment":72,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"interventions":[{"type":"DRUG","name":"vatreptacog alfa (activated)","otherNames":[]},{"type":"DRUG","name":"eptacog alfa (activated)","otherNames":[]}],"arms":[{"label":"rFVIIa","type":"EXPERIMENTAL"},{"label":"vatreptocog alfa","type":"EXPERIMENTAL"}],"summary":"This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.","primaryOutcome":{"measure":"Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given","timeFrame":"Within 12 hours of first trial product administration","effectByArm":[{"arm":"Vatreptacog Alfa 80 µg/kg","deltaMin":22,"sd":null},{"arm":"rFVIIa 90 µg/kg","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":32,"countries":["United States","Austria","Brazil","Croatia","Greece","Hungary","Italy","Japan","Malaysia","Poland","Puerto Rico","Romania","Russia","Serbia","South Africa","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":72},"commonTop":["Drug specific antibody present"]}}